Finland · Delayed Price · Currency is EUR Orion Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Net sales and operating profit surged in Q2 and H1 2026, driven by Nubeqa royalties and Branded Products. Guidance was raised, with continued growth expected in Innovative Medicines and stable performance in other divisions. Tariffs and shipment timing pose minor risks.
-
Q1 2026 saw strong growth across all divisions, with net sales up 18% and operating profit up 47% year-over-year. Upgraded full-year guidance reflects robust performance, especially in Innovative Medicines, and reduced downside risk from US tariffs.
-
Strong growth is driven by innovative oncology medicines, especially Nubeqa, with robust financial targets through 2028. Expansion into the US and Asia-Pacific, a diversified pipeline, and a flexible dividend policy support long-term global ambitions.
Fiscal Year 2025
-
Record 2025 results driven by Nubeqa milestone, strong growth across all divisions, and robust R&D progress. 2026 guidance anticipates higher sales, profit, and continued investment in pipeline and capacity. Dividend of €1.80 per share proposed.
-
Nubeqa drove record royalties and strong growth in innovative medicines, while generics and consumer health also performed well. Guidance was narrowed as year-end visibility improved, with R&D and U.S. pricing remaining key uncertainties.
-
Q2 2025 saw strong growth across all divisions, with net sales up 27% and operating profit up 59% year-over-year, driven by innovative medicines and Nubeqa royalties. Updated guidance reflects continued momentum but maintains a wide range due to uncertainties in royalties, R&D timing, and market factors.
-
Achieved key financial targets ahead of schedule and set ambitious growth plans through geographic expansion, portfolio transformation, and increased R&D investment. Focus areas include innovative medicines, branded products, generics, and animal health, with robust financial discipline and readiness for strategic acquisitions.
-
Q1 2025 saw 15% net sales and 39% operating profit growth, led by innovative medicines and strong Nubeqa sales. Guidance for the year remains unchanged, with ongoing R&D expansion and a new phase III project for Levosimendan.
-
Strong growth is driven by geographic expansion, innovative oncology products, and a diversified portfolio. Nubeqa has reached blockbuster status, and the pipeline includes promising oncology and insomnia drugs. Financial targets through 2028 emphasize sustained growth and shareholder returns.
Fiscal Year 2024
-
2024 saw nearly 30% sales growth, driven by Nubeqa and milestone payments, with strong cash flow and a 33% rise in operating profit. 2025 guidance reflects Nubeqa's growing impact, wider ranges due to R&D and FX uncertainty, and no major milestones expected. Nubeqa now represents 34% of revenue.
-
Q3 saw strong growth driven by milestone payments and robust performance in key divisions, with net sales up 16.6% year-to-date and operating profit rising EUR 42 million. R&D focus shifts after project cancellations, but long-term growth targets and 2024 guidance remain unchanged.
-
Q2 and H1 2024 saw strong growth in net sales and operating profit, driven by Nubeqa, Easyhaler, and Animal Health. Outlook for 2024 was upgraded, supported by milestone payments and improved cash flow. No major headwinds are expected for H2, with R&D costs rising but within guidance.